Company profile
Home | Avacta Life Sciences Limited
We develop safe and efficacious drugs, and powerful research and diagnostic tools, based on our proprietary Affimer and pre|CISION platforms
Updated 06 Jun 2026 16:52
Reference milestones and recent Companies House filing stream events.
Next confirmation statement due date
Next accounts due date
Last confirmation statement made up date
Last accounts made up date
TM01 | Transaction MzQzODU0NzAzMmFkaXF6a2N4
Published 07 Oct 2024 06:39
AD01 | Transaction MzQzODQ1MTIxNmFkaXF6a2N4
Published 04 Oct 2024 04:15
Company registered at Companies House
1 Nov 2015 to 31 May 2018
To validate multiplexed tests using Affimer technology for early detection of bacterial infections and sepsis
1 Jun 2014 to 31 Aug 2016
Promexus is a new biotechnology company which will be developing a novel human therapeutic protein (the Affimer) that will address some of the shortcomings of the current antibody based drugs. Antibodies have been very successful at treating a wide range of human disease such as asthma, arthritis and cancer, but they are expensive to produce and because o...
